Search Results

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

Planegg/Munich, Germany, December , - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study, an P…

Loxley

In early September of , my son started to complain of back pain. I took him to the pediatrician, where he was assessed and a multiview was ordered. I…

COVID Updates: Where We Are and Where We Go From Here

We invite you to learn more about: How has evolved Safety tips for immunocompromised patients Current treatment advances Living with COVID thr…

Explaining Cancer to Students: A Classroom Presentation

This classroom presentation demonstrates how to talk to children about their classmate with cancer, including understanding key words, answering commo…

A Panel Discussion on Transitioning Your Student Back to School: Practical Tips and Advice

Watch this informative panel discussion of school personnel for practical tips on supporting a student attending school during or after cancer treatme…

Shameel

Telling a child that they have cancer and explaining what that means is one of the most difficult conversations you can have with your child.Shameel w…

Sarah

My daughter Sarah was a fun, smart, and scrappy kid. She was a great student, was involved in Student Council, was President of her class, played in t…

NCI Genetic Epidemiology Branch- Familial Blood and Lymph Node Cancers

To study families with multiple cases of lymphoproliferative disorders. The National Cancer Institute (NCI) of the National Institutes of Health…

FDA Approves the First-in-Class Bispecific Antibody for Treatment of Follicular Lymphoma

“This new treatment has the potential to help patients with this cancer achieve remission,” says LLS Chief Scientific Officer Dr. Lee Greenberger.

Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million ($57M USD)

Krakow, Poland – December , – Ryvu Therapeutics [WSE:RVU], a drug discovery and development company focusing on novel small molecule therapies that …

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

WALTHAM, Mass., January , – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and devel…

Insured Cancer Patients Continue to Face Barriers To Medically Necessary Treatment, New Report Warns

The new report published by The Leukemia & Lymphoma Society and Manatt Health offers concrete policy solutions.

Asistencia Financiera Dental para Veteranos

¿TIENES DEUDA MEDICA? ES POSIBLE QUE Blood Cancer United PUEDA AYUDARHaga clic aquí para obtener más información Esta página contiene información sobr…

What’s Next in Blood Cancer: Looking Ahead to 2023

The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December. This meeting, followed closely b…

A phase 1/2 study of BI-1206, a monoclonal antibody to CD32b (FcyRIIB), in combination with rituximab and acalabrutinib in patients with indolent NHL that has relapsed or is refractory to rituximab

In January , LLS made an equity investment in BioInvent to "Support Clinical Development of for NHL Indications and for Lymphoma Indications Includ…

BioInvent

BioInvent International AB is a biotech company that discovers and develops novel and antibodies for cancer therapy, with currently four drug candi…

BioInvent Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Receives $3 Million Strategic Equity Investment

Lund, Sweden – January , – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and developm…

Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies

January , - TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focuse…

The Ruth Cheatham Foundation

The Ruth Cheatham Foundation (TRCF) champions adolescents in their fight against cancer, while inspiring hope and providing resources for survivors to…

Special Days Camps

To provide a safe and memorable camping opportunity in a environment for children who have experienced cancer and their siblings, servicing the entir…

FDA Approves New Type of BTK Inhibitor to Treat Mantle Cell Lymphoma

The U.S. Food and Drug Administration today approved pirtobrutinib (Jaypirca™), the first , reversable BTK inhibitor for the treatment of adults with …

LLS Community Corner Log In Instructions

Click Link to Join: https://tlls.zoom.us/j/?pwd=S0pRTXd0bGRRSytydUk3bFBCeVcwZz09 Do I need to be on camera? No, you will be asked if you would like t…

Language Matters: What Supporters Say is Not Always What People with Cancer Hear